Thakur Gurjeet Singh, PhD, MPharm, has 16 years of experience in industry, research, and teaching. He is currently Dean of the Chitkara College of Pharmacy, Chitkara University, Punjab, India. He is engaged with projects on interception of nicotine, morphine, alcohol dependence, ischemia, diabetic neuropathy and nephropathy toxicology, epilepsy, Alzheimer’s disease, and stem cell research studies. He has attended UGC networking courses and various preclinical and clinical research training programs. A prolific author and researcher, he has many publications and patents to his credit. He has attended national and international conferences and has guided MPharm and PhD students. He is a reviewer for various highly reputed international journals. Dr. Singh is a member secretary of the Committee for the Purpose of Control and Supervision of Experiments on Animals and is the In-Charge of the animal house facility at the Chitkara College of Pharmacy.Heena Khan, PhD, MPharm, has over five years of experience in research. She is working as a Research Fellow at Chitkara University, Punjab, India, where she is engaged with several projects on stroke, diabetes, Alzheimer’s disease, and Parkinson’s disease. She has more than 30 research and review publications to her credit and is a reviewer for several international journals. She has participated and attended several national and international conferences. She is also a member of the International Society for Pharmacoeconomics and Outcomes Research.

• 1. Stroke Insight 2. Myocardial Ischemic-Reperfusion Injury 3. Preclinical and Clinical Aspects of I-R Injuries 4. Molecular Aspects of Ischemic-Reperfusion Injury 5. Role of Mitochondria in Ischemic-Reperfusion Injury 6. Stroke Effect in Daily Life and Therapeutics, Complications for Prevention of Stroke 7. Etiopathogenesis and Molecular Targets in Cerebral Ischemia: Current Understanding of Stroke and Therapeutic Approaches 8. Expatiating the Pivotal Role of Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Ischemic Stroke: Molecular Insights and Therapeutic Targets 9. Acute Ischemic Stroke in COVID-19 Patients 10. Neurotransmission Imbalance: A Major Factor in the Worsening of Ischemic Injury 11. Role of the Renin-Angiotensin-Aldosterone System (RAAS) in Amelioration of Stroke Pathophysiology 12. Stroke and Diabetes in Vitamin D Deficiency: Prospects of Intertwined Pathobiologies 13. Remote Ischemic Post-Conditioning: An Overview 14. Sex-Based Differences in Acute Kidney Injury: Lessons from Renal Ischemia-Reperfusion Injury Model in Rodents 15. Critical Overview of Conditioning Techniques and Their Current Status in the Treatment of Myocardial Ischemia-Reperfusion Injury 16. Involvement of Platelets in Myocardial Ischemia and Reperfusion Injury 17. Recent Advancements in Strategies for Treatment of Cerebral Ischemia 18. Recent Therapeutic Approaches Toward the Management of Ischemic Heart Disease 19. Nanotechnology-Assisted Treatment for Ischemic Heart Disease and Recent Patents 20. Major Risk Factors Involved in the Pathobiology of Ischemic Brain and Heart Disorders 21. Modulating Mitogen-Activated Protein Kinase (MAPK) Downstream Signaling Pathways in Cerebral Ischemic Hemorrhages 22. Implication of Mitogen-Activated Protein Kinase (MAPK) in Cerebral Stroke 23. Regulation of JNK Signaling Pathway in Ischemia-Reperfusion Injury 24. Role of Glycogen Synthase Kinase-3? (Gsk-3?) in Intracranial Haemorrhage 25. Role of GSK-3 Inhibition in Modulating the Pathology of Stroke 26. Regulation of NRF-2 Signaling Pathway in Ischemia-Reperfusion Injury 27. Regulation of PI3K-AKT Signaling Pathway in Ischemia-Reperfusion Injury 28. COVID-19 and Ischemic Stroke: Advancements and Challenges

Thakur Gurjeet Singh, PhD, MPharm, has 16 years of experience in industry, research, and teaching. He is currently Dean of the Chitkara College of Pharmacy, Chitkara University, Punjab, India. He is engaged with projects on interception of nicotine, morphine, alcohol dependence, ischemia, diabetic neuropathy and nephropathy toxicology, epilepsy, Alzheimer’s disease, and stem cell research studies. He has attended UGC networking courses and various preclinical and clinical research training programs. A prolific author and researcher, he has many publications and patents to his credit. He has attended national and international conferences and has guided MPharm and PhD students. He is a reviewer for various highly reputed international journals. Dr. Singh is a member secretary of the Committee for the Purpose of Control and Supervision of Experiments on Animals and is the In-Charge of the animal house facility at the Chitkara College of Pharmacy.Heena Khan, PhD, MPharm, has over five years of experience in research. She is working as a Research Fellow at Chitkara University, Punjab, India, where she is engaged with several projects on stroke, diabetes, Alzheimer’s disease, and Parkinson’s disease. She has more than 30 research and review publications to her credit and is a reviewer for several international journals. She has participated and attended several national and international conferences. She is also a member of the International Society for Pharmacoeconomics and Outcomes Research.

• 1. Stroke Insight 2. Myocardial Ischemic-Reperfusion Injury 3. Preclinical and Clinical Aspects of I-R Injuries 4. Molecular Aspects of Ischemic-Reperfusion Injury 5. Role of Mitochondria in Ischemic-Reperfusion Injury 6. Stroke Effect in Daily Life and Therapeutics, Complications for Prevention of Stroke 7. Etiopathogenesis and Molecular Targets in Cerebral Ischemia: Current Understanding of Stroke and Therapeutic Approaches 8. Expatiating the Pivotal Role of Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Ischemic Stroke: Molecular Insights and Therapeutic Targets 9. Acute Ischemic Stroke in COVID-19 Patients 10. Neurotransmission Imbalance: A Major Factor in the Worsening of Ischemic Injury 11. Role of the Renin-Angiotensin-Aldosterone System (RAAS) in Amelioration of Stroke Pathophysiology 12. Stroke and Diabetes in Vitamin D Deficiency: Prospects of Intertwined Pathobiologies 13. Remote Ischemic Post-Conditioning: An Overview 14. Sex-Based Differences in Acute Kidney Injury: Lessons from Renal Ischemia-Reperfusion Injury Model in Rodents 15. Critical Overview of Conditioning Techniques and Their Current Status in the Treatment of Myocardial Ischemia-Reperfusion Injury 16. Involvement of Platelets in Myocardial Ischemia and Reperfusion Injury 17. Recent Advancements in Strategies for Treatment of Cerebral Ischemia 18. Recent Therapeutic Approaches Toward the Management of Ischemic Heart Disease 19. Nanotechnology-Assisted Treatment for Ischemic Heart Disease and Recent Patents 20. Major Risk Factors Involved in the Pathobiology of Ischemic Brain and Heart Disorders 21. Modulating Mitogen-Activated Protein Kinase (MAPK) Downstream Signaling Pathways in Cerebral Ischemic Hemorrhages 22. Implication of Mitogen-Activated Protein Kinase (MAPK) in Cerebral Stroke 23. Regulation of JNK Signaling Pathway in Ischemia-Reperfusion Injury 24. Role of Glycogen Synthase Kinase-3? (Gsk-3?) in Intracranial Haemorrhage 25. Role of GSK-3 Inhibition in Modulating the Pathology of Stroke 26. Regulation of NRF-2 Signaling Pathway in Ischemia-Reperfusion Injury 27. Regulation of PI3K-AKT Signaling Pathway in Ischemia-Reperfusion Injury 28. COVID-19 and Ischemic Stroke: Advancements and Challenges

Thakur Gurjeet Singh, PhD, MPharm, has 16 years of experience in industry, research, and teaching. He is currently Dean of the Chitkara College of Pharmacy, Chitkara University, Punjab, India. He is engaged with projects on interception of nicotine, morphine, alcohol dependence, ischemia, diabetic neuropathy and nephropathy toxicology, epilepsy, Alzheimer’s disease, and stem cell research studies. He has attended UGC networking courses and various preclinical and clinical research training programs. A prolific author and researcher, he has many publications and patents to his credit. He has attended national and international conferences and has guided MPharm and PhD students. He is a reviewer for various highly reputed international journals. Dr. Singh is a member secretary of the Committee for the Purpose of Control and Supervision of Experiments on Animals and is the In-Charge of the animal house facility at the Chitkara College of Pharmacy.Heena Khan, PhD, MPharm, has over five years of experience in research. She is working as a Research Fellow at Chitkara University, Punjab, India, where she is engaged with several projects on stroke, diabetes, Alzheimer’s disease, and Parkinson’s disease. She has more than 30 research and review publications to her credit and is a reviewer for several international journals. She has participated and attended several national and international conferences. She is also a member of the International Society for Pharmacoeconomics and Outcomes Research.

• 1. Stroke Insight 2. Myocardial Ischemic-Reperfusion Injury 3. Preclinical and Clinical Aspects of I-R Injuries 4. Molecular Aspects of Ischemic-Reperfusion Injury 5. Role of Mitochondria in Ischemic-Reperfusion Injury 6. Stroke Effect in Daily Life and Therapeutics, Complications for Prevention of Stroke 7. Etiopathogenesis and Molecular Targets in Cerebral Ischemia: Current Understanding of Stroke and Therapeutic Approaches 8. Expatiating the Pivotal Role of Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Ischemic Stroke: Molecular Insights and Therapeutic Targets 9. Acute Ischemic Stroke in COVID-19 Patients 10. Neurotransmission Imbalance: A Major Factor in the Worsening of Ischemic Injury 11. Role of the Renin-Angiotensin-Aldosterone System (RAAS) in Amelioration of Stroke Pathophysiology 12. Stroke and Diabetes in Vitamin D Deficiency: Prospects of Intertwined Pathobiologies 13. Remote Ischemic Post-Conditioning: An Overview 14. Sex-Based Differences in Acute Kidney Injury: Lessons from Renal Ischemia-Reperfusion Injury Model in Rodents 15. Critical Overview of Conditioning Techniques and Their Current Status in the Treatment of Myocardial Ischemia-Reperfusion Injury 16. Involvement of Platelets in Myocardial Ischemia and Reperfusion Injury 17. Recent Advancements in Strategies for Treatment of Cerebral Ischemia 18. Recent Therapeutic Approaches Toward the Management of Ischemic Heart Disease 19. Nanotechnology-Assisted Treatment for Ischemic Heart Disease and Recent Patents 20. Major Risk Factors Involved in the Pathobiology of Ischemic Brain and Heart Disorders 21. Modulating Mitogen-Activated Protein Kinase (MAPK) Downstream Signaling Pathways in Cerebral Ischemic Hemorrhages 22. Implication of Mitogen-Activated Protein Kinase (MAPK) in Cerebral Stroke 23. Regulation of JNK Signaling Pathway in Ischemia-Reperfusion Injury 24. Role of Glycogen Synthase Kinase-3? (Gsk-3?) in Intracranial Haemorrhage 25. Role of GSK-3 Inhibition in Modulating the Pathology of Stroke 26. Regulation of NRF-2 Signaling Pathway in Ischemia-Reperfusion Injury 27. Regulation of PI3K-AKT Signaling Pathway in Ischemia-Reperfusion Injury 28. COVID-19 and Ischemic Stroke: Advancements and Challenges